Archive

Sex Differences in Early Functional Outcomes After Acute Stroke: A Retrospective Cohort Study at a United Kingdom Tertiary Stroke Centre

Unadjusted, women had worse discharge mRS (common OR 1.34, 95% CI 1.10–1.64). After adjusting for age and pre-stroke mRS the association fell to 0.95 (95% CI 0.77–1.16) and fully adjusted 0.94 (0.76–1.16).

Neurology · Cureus · 17 Sept

Suspected Bulbar-Predominant Myasthenia Gravis Exacerbation in an Older Adult With Respiratory Deterioration and Silent Aspiration: A Case Report

Videofluoroscopy showed significant silent aspiration of thin and mildly thickened liquids; serial blood gases showed persistent hypercapnia with preserved pH and markedly elevated bicarbonate. Respiratory status stabilized on IVIG and steroids, but bulbar dysfunction and dysphagia persisted.

Neurology · Cureus · 17 Sept

Not All Transverse Sinus Stenoses Behave the Same: Distinct Flow Phenotypes on Phase-Contrast MRI

Mean peak velocity was 16.97 cm/s proximal, 12.84 cm/s intra-stenotic and 14.82 cm/s distal. Ten segments (55.6%) were low-flow, seven (38.9%) jet, one (5.6%) intermediate.

Neurology · Cureus · 17 Sept

Closed-Loop Neuroprosthetics: Advancing Long-Term Solutions for Brain-Level Function Restoration

No usable figures reported. Author attributes failure to reach clinical practice to material fatigue, electrode degradation, inflammation and electrical drift degrading sensing and stimulation over time.

Neurology · Cureus · 16 Sept

Novartis ends ALS program after phase 2 flop, adding to R&D woes

Another negative ALS trial leaves your patients with no new disease-modifying option; enrolment in remaining ALS studies is now the only route to change that.

Neurology · Fierce Biotech · 16 Sept

The Mask of Delirium: Uncovering a Presumed Cardioembolic Stroke Through Comprehensive Clinical Evaluation

MRI confirmed acute left temporal restricted diffusion; troponin I was 1026.3 and 1060.5 ng/L, NT-proBNP 7451 pg/mL, and ejection fraction 15% to 20%.

Neurology · Cureus · 16 Sept

EBV reactivation priming of the peripheral immune system in multiple sclerosis relapse.

Supports EBV-directed monitoring or antiviral strategies as a way to anticipate and possibly prevent MS relapses in your RRMS patients.

Neurology · Nature Medicine · 16 Sept

Revascularization in Asymptomatic Carotid Artery Stenosis With Hemodynamic Impairment and Cognitive Outcomes: The CREST-H Substudy of the CREST-2 Randomized Clinical Trial.

No treatment difference in cognitive z score over 1 year: adjusted difference -0.15 SD (95% CI, -0.54 to 0.24). Treatment × hemodynamic interaction not significant (β=0.018; 95% CI, -0.025 to 0.061; P=.40)

Neurology · JAMA · 16 Sept

Revascularization of Asymptomatic Carotid Artery Stenosis: Cognitive Results of the CREST-2 Randomized Trials.

No between-group difference in adjusted composite z score at 4 years: CAS trial 0.03 (95% CI, -0.09 to 0.15); CEA trial 0.02 (95% CI, -0.09 to 0.14). No individual test differed.

Neurology · JAMA · 16 Sept

External Lumbar Drainage for Refractory Intracranial Hypertension in Acute Brain Injury: A Narrative Review and Case Series

In refractory ICP above 22 mmHg despite maximal therapy, ELD may lower pressure without decompressive craniectomy, but case selection and herniation risk remain unresolved.

Neurology · Cureus · 16 Sept

Memantine-Induced Sialorrhea: A Rare Adverse Reaction and Review of Pathophysiological Mechanisms

If a dementia patient on memantine develops unexplained drooling, consider the drug as the cause rather than assuming progression or a new neurological deficit.

Neurology · Cureus · 15 Sept

Effectiveness of Virtual Reality-Based Rehabilitation on Balance, Gait, and Functional Independence in Patients With Parkinson’s Disease: Implications for Healthy Longevity

Berg Balance Scale improved +8.97 versus +4.52 points, TUG −3.51 versus −1.79 seconds, gait speed +0.234 versus +0.111 m/s; 108 of 125 (86.4%) versus 34 of 125 (27.2%) reached lower fall-risk category.

Neurology · Cureus · 15 Sept

Axoltis misses the mark in phase 2 ALS study, but still strives to move towards the clinic

A negative phase 2 in ALS means no new option is imminent; continue standard multidisciplinary care and consider enrolling patients in other ongoing ALS trials.

Neurology · Fierce Biotech · 14 Sept

Persistent HyperCKemia Beyond Post-Viral Myositis: A Case of Anti-HMGCR Immune-Mediated Necrotizing Myopathy

CK fell to 376 U/L (N 30-200 U/L) four months after admission on high-dose corticosteroids then methotrexate, with complete recovery of muscle strength and swallowing.

Neurology · Cureus · 14 Sept

Idiopathic Normal Pressure Hydrocephalus: A Review.

Gait disturbance occurs in 85%-95%, urinary dysfunction in 75%-90%, cognitive impairment in 60%-80%. After shunting, gait velocity improves in 75%-80%, cognition and urinary symptoms in 50%-70%.

Neurology · JAMA · 14 Sept

Beat-to-Beat Nystagmus Differentiation Between Benign Paroxysmal Positional Vertigo (BPPV) and Vestibular Migraine (VM): A Cross-Sectional Videonystagmographic Study From Northern India

Peak nystagmus amplitude and slow-phase velocity were higher in BPPV (mean peak amplitude 11.55° vs 5.64°, p=0.02; mean peak SPV 21.16°/s vs 13.10°/s, p=0.005).

Neurology · Cureus · 13 Sept

Systematic Review and Meta-Analysis on Central and/or Peripheral Nervous System Demyelination in Patients Treated With Tumor Necrosis Factor Alpha (TNF-α) Inhibitors

Pooled random-effects estimates: RR 1.46 (95% CI 1.09-1.95) for CNS demyelination and RR 2.00 (95% CI 1.19-3.38) for PNS demyelination.

Neurology · Cureus · 11 Sept

Cardiac Metastasis From Lung Cancer: A Hidden Cardioembolic Source of Acute Ischemic Stroke

Brain MRI showed multiple acute ischemic infarcts in the left middle cerebral artery territory; cardiac imaging found a left ventricular mass suggestive of metastasis. She died one year later.

Neurology · Cureus · 11 Sept

Jugular Venous Compression via Soft Cervical Collar in Shunt-Refractory Low-Pressure Hydrocephalus: A Report of Two Cases

Third ventricular width decreased from 13 to 8 mm in case 1 and 13 to 4 mm in case 2; ventriculomegaly recurred on collar cessation and resolved on reapplication in case 1

Neurology · Cureus · 11 Sept

Beyond clinical endpoints: Rethinking ALS drug development through disease biology

If biology-driven endpoints replace survival and ALSFRS-R in ALS trials, the drugs you can offer patients may change faster than current approval standards allow.

Neurology · Fierce Biotech · 11 Sept

Neurosurgical Outcomes of Epilepsy Surgery Between 2017 and 2025: A Retrospective ESSQ-19 Study From a Tertiary Care Center

ESSQ-19 summary score was 84.1±21.7. Surgical complication domain scored 89.2±21.1 and seizure control 85.0±27.6, while psychosocial domain scored lower at 79.9±24.1.

Neurology · Cureus · 11 Sept

Preservation of Non-nidal Medial Veins During Microsurgical Resection of Cerebral Arteriovenous Malformations: Technical Considerations and Early Clinical Outcomes

Complete angiographic nidus eradication in all 16 patients, no perioperative mortality, and mRS 0-2 in 14 patients (87.5%). No delayed venous infarction or haemorrhagic transformation occurred.

Neurology · Cureus · 11 Sept

Joint impact of pathological burden and cognitive resilience on Alzheimer's disease risk.

Incident AD dementia: pathology hazard ratio 2.50 per s.d. (95% CI 2.30-2.72); resilience hazard ratio 0.51 per s.d. (95% CI 0.48-0.55). The two interacted multiplicatively.

Neurology · Nature Medicine · 11 Sept

Mass Effect Score Associations in Comatose Trauma Patients With Intracranial Hemorrhage Requiring Mechanical Ventilation: A Retrospective Study

Mortality and adverse outcomes were associated with MES ≥2 (both p 0.05). Failure to follow commands at three months was also associated with MES ≥2 (p 0.05).

Neurology · Cureus · 10 Sept

When Speech Signals Wilson Disease: A Case Report

Kayser-Fleischer rings, reduced serum ceruloplasmin, elevated 24-hour urinary copper, decompensated liver disease, and MRI signal changes in basal ganglia, thalami, and periventricular white matter confirmed Wilson disease; D-penicillamine and zinc led to clinical improvement

Neurology · Cureus · 10 Sept

Tumor-Related Trigeminal Neuralgia: Clinical Features, Pathophysiology, and the Contemporary Role of Radiosurgery in Tumor Control and Pain Relief

Microsurgery gave a higher proportion of favourable pain outcomes and, in one meta-analysis, longer median time to pain recurrence, with equivalent tumor control, mainly in petroclival and petrous apex meningioma.

Neurology · Cureus · 10 Sept

Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal

If you have patients on or awaiting BHV-7000 trials, recruitment is now paused pending rodent toxicity review, so discuss alternatives rather than enrolment timelines.

Neurology · Fierce Biotech · 10 Sept

Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial.

At 90 days, 69.7% on loberamisal reached mRS 0-1 versus 56.3% on placebo (risk difference 13.28%, 95% CI 7.24%-19.32%)

Neurology · JAMA · 10 Sept

Surgical Deconstruction of Recurrent Basilar Apex Aneurysms Refractory to Endovascular Treatment

Both patients achieved safe, immediate and durable aneurysm disconnection; angiographic posterior communicating artery presence and an intraoperative perforator-free zone were key to the approach

Neurology · Cureus · 9 Sept

Diagnostic Diplopia: Isolated Oculomotor Nerve Palsy With Normal Imaging

When imaging is normal in isolated oculomotor palsy, don't settle for microvascular cause—consider vasculitis, aneurysm, or infiltrative disease before discharging.

Neurology · Cureus · 9 Sept

Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.

MWT sleep latency rose 14.3-19.8 minutes with oveporexton versus -0.4 to -0.8 with placebo; ESS fell 9.7-11.8 versus 1.5-1.7; cataplexy fell 79.0-88.8% versus 27.7-39.1% (all P<0.001).

Neurology · NEJM · 9 Sept

Deepinder Goyal’s Temple Takes First Step Towards Validating Its Wearable

If validated, this wearable could offer non-invasive brain flow monitoring in clinics, aiding early detection of neurological conditions.

Neurology · Inc42 · 7 Sept

Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

First therapy for Alexander disease—an ASO targeting GFAP—offers a disease-modifying option for a fatal leukodystrophy, though availability in India remains unclear.

Neurology · Fierce Biotech · 4 Sept

FDA Approves First Drug to Treat Alexander Disease

First-ever therapy for a fatal leukodystrophy; consider referral for pediatric or adult patients with confirmed GFAP mutation.

Neurology · FDA — Press Announcements · 4 Sept

Psilocybin proves promising in neuropathic pain mouse study

If confirmed in humans, psilocybin could offer a new option for chemotherapy-induced neuropathy, which often resists standard painkillers.

Neurology · Fierce Biotech · 3 Sept

Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study.

Cumulative incidence of epilepsy increased from 9.5% (95% CI 7.8-11.3) at Alzheimer's diagnosis to 56.9% (51.7-61.7) after 9 years. Epilepsy associated with increased mortality (HR 2.10 [95% CI 1.57-2.82]; p<0.0001) and faster cognitive decline.

Neurology · Lancet · 3 Sept

Mechanical Thrombectomy in Ischemic Stroke With Medium or Distal Arterial Occlusion

For stroke patients with medium or distal occlusions, this trial clarifies whether adding thrombectomy to medical therapy improves outcomes—directly guiding your reperfusion decisions.

Neurology · JAMA · 1 Sept

Mechanical Thrombectomy in Ischemic Stroke With a Medium or Distal Arterial Occlusion Research Summary

For stroke patients with medium or distal clots, this trial tests whether adding thrombectomy to standard care improves functional recovery—directly informing your reperfusion decisions.

Neurology · JAMA · 1 Sept

One-Year Outcomes After Endovascular Treatment for Large Acute Ischemic Stroke

Confirms thrombectomy benefit persists at 1 year for large-core strokes, supporting its use in patients you might otherwise manage medically.

Neurology · JAMA · 1 Sept

FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

For adults with narcolepsy type 1, this first full-spectrum oral option may reduce cataplexy and sleepiness, offering an alternative to stimulants and sodium oxybate.

Neurology · FDA — Press Announcements · 6 Aug